Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu.
1995 · Journal of Clinical Oncology · 183 citations
https://doi.org/10.1200/jco.1995.13.9.2281
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
0
Papers
0
Citations
R F Graziano is an academic researcher.
https://doi.org/10.1200/jco.1995.13.9.2281
https://doi.org/10.4049/jimmunol.143.5.1650
https://doi.org/10.4049/jimmunol.158.7.3090
https://doi.org/10.4049/jimmunol.155.10.4996
https://doi.org/10.1089/scd.1.1995.4.471
Click to start Chat